{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T15:10:11Z","timestamp":1722179411272},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2013,4,21]],"date-time":"2013-04-21T00:00:00Z","timestamp":1366502400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1007\/s00406-013-0406-3","type":"journal-article","created":{"date-parts":[[2013,4,20]],"date-time":"2013-04-20T01:47:18Z","timestamp":1366422438000},"page":"633-641","source":"Crossref","is-referenced-by-count":14,"title":["Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"263","author":[{"given":"Taro","family":"Kishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Hirota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,21]]},"reference":[{"key":"406_CR1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/JCP.0b013e3182686619","volume":"32","author":"Y Albayrak","year":"2012","unstructured":"Albayrak Y, Ekinci O (2012) Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case report. J Clin Psychopharmacol 32:723\u2013724","journal-title":"J Clin Psychopharmacol"},{"key":"406_CR2","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archpsyc.1982.04290070020005","volume":"39","author":"NC Andreasen","year":"1982","unstructured":"Andreasen NC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39:784\u2013788","journal-title":"Arch Gen Psychiatry"},{"key":"406_CR3","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/schbul\/11.3.380","volume":"11","author":"NC Andreasen","year":"1985","unstructured":"Andreasen NC (1985) Positive vs. negative schizophrenia: a critical evaluation. Schizophr Bull 11:380\u2013389","journal-title":"Schizophr Bull"},{"key":"406_CR4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-2999(99)00769-4","volume":"386","author":"DT Ault","year":"1999","unstructured":"Ault DT, Werling LL (1999) Phencyclidine and dizocilpine modulate dopamine release from rat nucleus accumbens via sigma receptors. Eur J Pharmacol 386:145\u2013153","journal-title":"Eur J Pharmacol"},{"key":"406_CR5","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0306-4522(96)00221-7","volume":"76","author":"P Bouchard","year":"1997","unstructured":"Bouchard P, Quirion R (1997) [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience 76:467\u2013477","journal-title":"Neuroscience"},{"key":"406_CR6","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1440-1819.2004.01269.x","volume":"58","author":"W Chaichan","year":"2004","unstructured":"Chaichan W (2004) Olanzapine plus fluvoxamine and olanzapine alone for the treatment of an acute exacerbation of schizophrenia. Psychiatry Clin Neurosci 58:364\u2013368","journal-title":"Psychiatry Clin Neurosci"},{"key":"406_CR7","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/01.jcp.0000096246.29231.73","volume":"23","author":"RR Conley","year":"2003","unstructured":"Conley RR, Kelly DL, Richardson CM, Tamminga CA, Carpenter WT Jr (2003) The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J Clin Psychopharmacol 23:668\u2013671","journal-title":"J Clin Psychopharmacol"},{"key":"406_CR8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molmed.2010.10.010","volume":"17","author":"CU Correll","year":"2011","unstructured":"Correll CU, Lencz T, Malhotra AK (2011) Antipsychotic drugs and obesity. Trends Mol Med 17:97\u2013107","journal-title":"Trends Mol Med"},{"key":"406_CR9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA, J Am Med Assoc 302:1765\u20131773","journal-title":"JAMA, J Am Med Assoc"},{"key":"406_CR10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188","journal-title":"Control Clin Trials"},{"key":"406_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1744-859X-9-11","volume":"9","author":"T Furuse","year":"2010","unstructured":"Furuse T, Hashimoto K (2010) Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors. Ann Gen Psychiatry 9:11","journal-title":"Ann Gen Psychiatry"},{"key":"406_CR12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1744-859X-9-17","volume":"9","author":"T Furuse","year":"2010","unstructured":"Furuse T, Hashimoto K (2010) Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases. Ann Gen Psychiatry 9:17","journal-title":"Ann Gen Psychiatry"},{"key":"406_CR13","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1046\/j.1471-4159.1995.65062509.x","volume":"65","author":"GM Gonzalez-Alvear","year":"1995","unstructured":"Gonzalez-Alvear GM, Thompson-Montgomery D, Deben SE, Werling LL (1995) Functional and binding properties of sigma receptors in rat cerebellum. J Neurochem 65:2509\u20132516","journal-title":"J Neurochem"},{"key":"406_CR14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0014-2999(99)00025-4","volume":"368","author":"B Gronier","year":"1999","unstructured":"Gronier B, Debonnel G (1999) Involvement of sigma receptors in the modulation of the glutamatergic\/nmda neurotransmission in the dopaminergic systems. Eur J Pharmacol 368:183\u2013196","journal-title":"Eur J Pharmacol"},{"key":"406_CR15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56\u201362","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"406_CR16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.npp.1301047","volume":"32","author":"K Hashimoto","year":"2007","unstructured":"Hashimoto K, Fujita Y, Iyo M (2007) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol 32:514\u2013521","journal-title":"Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol"},{"key":"406_CR17","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"406_CR18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s002139900351","volume":"149","author":"D Hinze-Selch","year":"2000","unstructured":"Hinze-Selch D, Deuschle M, Weber B, Heuser I, Pollmacher T (2000) Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology 149:163\u2013169","journal-title":"Psychopharmacology"},{"key":"406_CR19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0920-9964(01)00314-0","volume":"57","author":"T Inada","year":"2002","unstructured":"Inada T, Yagi G, Miura S (2002) Extrapyramidal symptom profiles in japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 57:227\u2013238","journal-title":"Schizophr Res"},{"key":"406_CR20","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.biopsych.2007.04.001","volume":"62","author":"M Ishikawa","year":"2007","unstructured":"Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M, Oda K, Miyatake R, Fujisaki M, Shimizu E, Shirayama Y, Iyo M, Hashimoto K (2007) High occupancy of sigma-1 receptors in the human brain after single oral administration of fluvoxamine: a positron emission tomography study using [11c]SA4503. Biol Psychiatry 62:878\u2013883","journal-title":"Biol Psychiatry"},{"key":"406_CR21","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.pnpbp.2008.01.005","volume":"32","author":"M Iyo","year":"2008","unstructured":"Iyo M, Shirayama Y, Watanabe H, Fujisaki M, Miyatake R, Fukami G, Shiina A, Nakazato M, Shiraishi T, Ookami T, Hashimoto K (2008) Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:1072\u20131073","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"406_CR22","doi-asserted-by":"crossref","unstructured":"Kay SR, Opler LA, Lindenmayer JP (1989) The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry (Suppl 7):59\u201367","DOI":"10.1192\/S0007125000291514"},{"issue":"2","key":"406_CR23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpsychires.2012.10.011","volume":"47","author":"T Kishi","year":"2013","unstructured":"Kishi T, Matsuda Y, Nakamura H, Iwata N (2013) Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res 47(2):149\u2013154. doi: 10.1016\/j.jpsychires.2012.10.011","journal-title":"J Psychiatr Res"},{"key":"406_CR24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.biopsych.2007.04.043","volume":"63","author":"S Kumra","year":"2008","unstructured":"Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, De Thomas C, Kafantaris V, Correll CU, Kane JM (2008) Clozapine and \u201chigh-dose\u201d olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 63:524\u2013529","journal-title":"Biol Psychiatry"},{"key":"406_CR25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","volume":"373","author":"S Leucht","year":"2009","unstructured":"Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31\u201341","journal-title":"Lancet"},{"key":"406_CR26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","volume":"166","author":"S Leucht","year":"2009","unstructured":"Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM (2009) A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152\u2013163","journal-title":"Am J Psychiatry"},{"key":"406_CR27","doi-asserted-by":"crossref","unstructured":"Li C, Xia J, Wang J (2009) Risperidone dose for schizophrenia. Cochrane Database Syst Rev CD007474","DOI":"10.1002\/14651858.CD007474.pub2"},{"key":"406_CR28","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4088\/JCP.v65n0607","volume":"65","author":"ML Lu","year":"2004","unstructured":"Lu ML, Lane HY, Lin SK, Chen KP, Chang WH (2004) Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry 65:766\u2013771","journal-title":"J Clin Psychiatry"},{"key":"406_CR29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-med-050911-161504","volume":"64","author":"HY Meltzer","year":"2013","unstructured":"Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393\u2013406","journal-title":"Annu Rev Med"},{"key":"406_CR30","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4088\/JCP.v69n0214","volume":"69","author":"HY Meltzer","year":"2008","unstructured":"Meltzer HY, Bobo WV, Roy A, Jayathilake K, Chen Y, Ertugrul A, Anil Yagcioglu AE, Small JG (2008) A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry 69:274\u2013285","journal-title":"J Clin Psychiatry"},{"key":"406_CR31","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry J Mental Sci 134:382\u2013389","journal-title":"Br J Psychiatry J Mental Sci"},{"key":"406_CR32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0014-2999(96)00254-3","volume":"307","author":"N Narita","year":"1996","unstructured":"Narita N, Hashimoto K, Tomitaka S, Minabe Y (1996) Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 307:117\u2013119","journal-title":"Eur J Pharmacol"},{"key":"406_CR33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/JCP.0b013e3182664cfc","volume":"32","author":"T Niitsu","year":"2012","unstructured":"Niitsu T, Fujisaki M, Shiina A, Yoshida T, Hasegawa T, Kanahara N, Hashimoto T, Shiraishi T, Fukami G, Nakazato M, Shirayama Y, Hashimoto K, Iyo M (2012) A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study. J Clin Psychopharmacol 32:593\u2013601","journal-title":"J Clin Psychopharmacol"},{"key":"406_CR34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.pnpbp.2010.06.007","volume":"34","author":"T Niitsu","year":"2010","unstructured":"Niitsu T, Shirayama Y, Fujisaki M, Hashimoto K, Iyo M (2010) Fluvoxamine improved cognitive impairments in a patient with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 34:1345\u20131346","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"406_CR35","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychol Rep 10:799\u2013812","journal-title":"Psychol Rep"},{"key":"406_CR36","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00004714-200008000-00004","volume":"20","author":"I Reznik","year":"2000","unstructured":"Reznik I, Sirota P (2000) Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol 20:410\u2013416","journal-title":"J Clin Psychopharmacol"},{"key":"406_CR37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.4088\/JCP.v68n0417","volume":"68","author":"AA Sepehry","year":"2007","unstructured":"Sepehry AA, Potvin S, Elie R, Stip E (2007) Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clinical Psychiatry 68:604\u2013610","journal-title":"J Clinical Psychiatry"},{"key":"406_CR38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00004850-200015050-00002","volume":"15","author":"H Silver","year":"2000","unstructured":"Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M (2000) Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 15:257\u2013261","journal-title":"Int Clin Psychopharmacol"},{"key":"406_CR39","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/0006-3223(92)90279-9","volume":"31","author":"H Silver","year":"1992","unstructured":"Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 31:698\u2013704","journal-title":"Biol Psychiatry"},{"key":"406_CR40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11\u201319","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"406_CR41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/bjp.bp.109.067710","volume":"197","author":"SP Singh","year":"2010","unstructured":"Singh SP, Singh V, Kar N, Chan K (2010) Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis. Br J Psychiatry J Mental Sci 197:174\u2013179","journal-title":"Br J Psychiatry J Mental Sci"},{"key":"406_CR42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0920-9964(96)00030-8","volume":"21","author":"JK Weatherspoon","year":"1996","unstructured":"Weatherspoon JK, Gonzalez-Alvear GM, Frank AR, Werling LL (1996) Regulation of [3H] dopamine release from mesolimbic and mesocortical areas of guinea pig brain by sigma receptors. Schizophr Res 21:51\u201362","journal-title":"Schizophr Res"},{"key":"406_CR43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s00213-002-1023-4","volume":"161","author":"Y Yamazaki","year":"2002","unstructured":"Yamazaki Y, Ishioka M, Matsubayashi H, Amano T, Sasa M (2002) Inhibition by sigma receptor ligand, MS-377, of N-methyl- D-aspartate-induced currents in dopamine neurons of the rat ventral tegmental area. Psychopharmacology 161:64\u201369","journal-title":"Psychopharmacology"},{"key":"406_CR44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/187231210791698483","volume":"4","author":"S Zambon","year":"2010","unstructured":"Zambon S, Fontana S, Kajbaf M (2010) Evaluation of cytochrome p450 inhibition assays using human liver microsomes by a cassette analysis\/LC-MS\/MS. Drug Metab Lett 4:120\u2013128","journal-title":"Drug Metab Lett"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-013-0406-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00406-013-0406-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-013-0406-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,12]],"date-time":"2019-07-12T17:37:38Z","timestamp":1562953058000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00406-013-0406-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,21]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["406"],"URL":"https:\/\/doi.org\/10.1007\/s00406-013-0406-3","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,21]]}}}